FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential ...
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
Kura Oncology, Inc.'s partnership and promising AML treatment make it a top stock pick with significant upside potential for ...
The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.
Gilead (GILD) announced that the FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with ...
Khaleej Times on MSN3h
UAE: Lupus treated at Abu Dhabi Stem Cells Centre using CAR-T Cell therapy for first time in Middle EastThree months after the therapy, the 60-year-old patient's platelet count and hemoglobin levels are stable, and her symptoms ...
SER-155 is an oral, 16-strain microbiome therapeutic that works by decolonizing gastrointestinal pathogens, strengthening the epithelial barrier, and inducing immune tolerance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback